Skip to main content
PLOS One logoLink to PLOS One
. 2020 Dec 9;15(12):e0243642. doi: 10.1371/journal.pone.0243642

Prevalence, socio-demographic and environmental determinants of asthma in 4621 Ghanaian adults: Evidence from Wave 2 of the World Health Organization’s study on global AGEing and adult health

Justice Moses K Aheto 1,*, Emilia A Udofia 2, Eugene Kallson 3, George Mensah 2, Minicuci Nadia 4, Naidoo Nirmala 5, Somnath Chatterji 5, Paul Kowal 5,6, Richard Biritwum 2, Alfred E Yawson 1,2
Editor: Florian Fischer7
PMCID: PMC7725342  PMID: 33296442

Abstract

Background

A previous multi-site study involving lower- and middle-income countries demonstrated that asthma in older adults is associated with long-term exposure to particulate matter, male gender and smoking. However, variations may occur within individual countries, which are relevant to inform health promoting policies as populations live longer. The present study estimates asthma prevalence and examines the sociodemographic characteristics and environmental determinants associated with asthma in older adults in Ghana.

Methods

This study utilised data from the nationally representative World Health Organization Study on global AGEing and adult health (SAGE) Ghana Wave 2. A final sample of 4621 individuals residing in 3970 households was used in analytical modelling. Factors associated with asthma were investigated using single level and multilevel binary logistic regression models.

Results

Asthma was reported by 102 (2.2%) respondents. Factors associated with asthma in the univariate model were: those aged 60–69 (OR = 5.22, 95% CI: 1.24, 21.95) and 70 or more (OR = 5.56, 95% CI: 1.33, 23.26) years, Ga-Adangbe dialect group (OR = 1.65, 95% CI: 1.01, 2.71), no religion (OR = 3.59, 95% CI: 1.77, 7.28), having moderate (OR = 1.76, 95% CI: 1.13, 2.75) and bad/very bad (OR = 2.75, 95% CI: 1.58, 4.80) health state, and severe/extreme difficulty with self-care (OR = 3.49, 95% CI: 1.23, 9.88) and non-flush toilet facility (OR = 0.62, 95% CI: 0.39, 0.99). Factors independently associated with asthma in the adjusted models were: those aged 60–69 (OR = 4.49, 95% CI: 1.03, 19.55) years, father with primary education or less (OR = 0.40, 95% CI: 0.17, 0.94), no religion (OR = 2.52, 95% CI: 1.18, 5.41), and households with non-flush toilet facility (OR = 0.58, 95% CI: 0.35, 0.96). Significant residual household-level variation in asthma was observed. Over 40% of variance in asthma episodes could be attributable to residual household-level variations.

Conclusion

Individual as well as household factors were seen to influence the prevalence of asthma in this national survey. Clinical management of these patients in health facilities should consider household factors in addition to individual level factors.

Introduction

Over 544 million people worldwide had a chronic respiratory disease (CRD) in the year 2017, representing a rise of 39·8% compared with 1990, with asthma (3.6%) remaining the second most prevalent CRD after chronic obstructive pulmonary disease (3.9%). Cumulatively, there was a slight reduction in asthma prevalence from 1990 (3.9%) to 2017 (3.6%) [1]. In 2015, over 3 million people worldwide died from asthma and chronic obstructive pulmonary disease, with an increase in prevalence of 12.6% between 1990 and 2015 particularly in lower income countries [2]. Asthma remains a concern even into older ages, where chronic obstructive pulmonary disease comorbidity is more often overlaid [3]. Asthma is a chronic inflammatory disorder of the airways characterized by bronchoconstriction and mucus plugs that limit airflow [4]. Asthma development is linked to complex interactions between genetic and environmental factors [5].

The Global Initiative for Asthma estimates that asthma affects 300 million people globally and 50 million people in Africa [6]. Asthma prevalence varies across Africa, as reported in several independent, cross-sectional studies providing country estimates of 2.7% in Cameroon (≥19 years) [7], 4.3% in Gambia (≥15 years) [8], 5.3% in Botswana (10–64 years) [9], 6.5% in Tunisia (2–52 years) [10], 6.8% in Uganda (≥35 years) [11], 6.9% in Kinshasa (≥18 years) [12] and 15.2% in Nigeria (18–65 years) [13]. The range of ages included in specific studies, along with differences in case definition, make comparisons difficult across countries in and outside of Africa. The differences observed within and between countries can be attributed to differences in ascertainment of asthma (symptom-based questionnaires and/or physician diagnosed), susceptible populations (genetic/host factors) and environmental exposures. The World Health Organization (WHO) estimates an annual national incidence rate of 1.5/1000 [5], compared to 2.8/1000 in Tunisia and 4.6/1000 in Algeria [14]. Asthma care is focused on prevention and management of asthmatic attacks, in addition to the use of medication to alleviate or control symptoms [15]. Both old age and poor asthma control are associated with impaired quality of life. A previous study using nationally representative data in Ghana, indicated that ageing was associated with a lower quality of life. The study indicated that relative younger age positively influenced subjective well-being among the older adult population [16].

Global literature indicates that risk factors for asthma include female sex [17], a family history [18], maternal smoking during pregnancy [19], obesity [20], family size [18, 21, 22], age [23], sex [23], reduced anti-oxidant intake [24, 25], urban residence [26, 27], reduced exposure to childhood infections [5] and consumption of fast foods, especially hamburgers [28]. Environmental exposures which might trigger attacks include bacterial endotoxins, particulate matter, ozone, cockroaches, and house dust mites [5, 17]. A study in South Africa demonstrated additional exposures in older adults including living within two kilometres of mine dumps and the use of paraffin as a cooking/heating fuel [29]. Jie and colleagues describe the most common indoor factors associated with asthma as mould growth and environmental tobacco smoke and fuel combustion, particularly biomass fuels [27]. Such indoor conditions may be facilitated under conditions where heating and ventilation are poor [30]. They also reported a higher prevalence in urban compared to rural adults and differences in prevalence correlated with exposure to house dust mites, higher levels of vehicle emissions and a westernized lifestyle among urban dwelling adults [27].

Grass mats, animal dander, obesity, helminthiasis, pesticides and female sex have also been reported as contributing factors in studies conducted in African countries [17]. A study conducted in China revealed that women, age, smoking, having a first degree relative with asthma or pollinosis, combined with allergic conditions such as eczema, allergic rhinitis and gastroesophageal reflux disease were associated with asthma [31]. Occupational exposure has been reported among gold miners (47.55%) in a study conducted in Obuasi, Ghana [32]. Nurses, poultry workers, hairdressers and wood cutters are other occupational groups at risk [17, 22].

Most studies providing evidence for risk factors in Ghana have been conducted among children [18, 33], while studies in older adults remain relatively limited. To address this gap, the present study examines socio-demographic and environmental determinants associated with asthma in older adults using data for Ghana from World Health Organization’s Study on global AGEing and adult health (SAGE).

Materials and methods

Data source and sampling

SAGE is a multi-country longitudinal study that collects data to complement existing ageing data sources to inform policy and programmes. Data from the SAGE Ghana Wave 2 nationally representative sample which is a household-based survey was used for this study. The study employed multistage cluster sampling strategies where clusters were systematically sampled with known non-zero selection probability and households residing in the selected clusters identified/listed and individuals in those selected households selected for interview. WHO and the University of Ghana Medical School Department of Community Health collaborated to implement SAGE Wave 2 in 2014–2015. Detailed description of the methods is published elsewhere [34].

Study population

Persons aged 50 years and above as well as a smaller sample of those aged 18–49 years were interviewed regarding their chronic health conditions and health services coverage, subjective wellbeing and quality of life, health care utilization, perceived health status, risk factors and preventive health behaviours, socio-demographic and work history, social cohesion and household characteristics. Further details about SAGE can be found through the WHO website (http://www.who.int/healthinfo/sage/cohorts/en/) including detailed information about SAGE Ghana Wave 2. In households identified as “older” for sampling purposes, all household members aged 50 years and older were invited to participate in the study.

Outcome variable

The primary outcome of interest was asthma status based on self-report based on the question, “Have you ever been diagnosed (by a doctor/health professional) with asthma (an allergic respiratory disease)?” The response was then categorised as having asthma (coded as 1) or no asthma (coded as 0).

Explanatory variables

The factors considered in this study included age, ethnicity, marital status, sex, father’s educational level, religion, health status report, household wall type, household source of drinking water, type of toilet facilities, household cooking fuel, toilet facilities shared, and household floor types.

Age was categorized into six age groups (18–29; 30–39; 40–49; 50–59; 60–69; ≥70), ethnicity into five main groupings (Akan, Ewe, Ga-Adangbe, Guan, Northern dialects), along with marital status (never married; currently married; co-habiting; separated/divorced; widowed), sex (male versus female), father’s educational level (no formal education; primary or less; secondary or higher), religion (some religion versus no religion), health status report (moderate versus bad/very bad), difficulty with self-care (mild; moderate; severe/extreme), household wall type (durable material versus non-durable material), household source of drinking water (piped versus non-piped), type of toilet facilities (flush versus non-flush), household cooking fuel (wood–primitive fuel; coal/charcoal/kerosene–transition fuel; electricity/gas–advanced fuel), toilet facilities shared (shared versus not shared), and household floor types (hard floor versus earth floor). Consideration of these variables were informed by the literature on factors that might influence chronic disease outcomes like asthma, especially in lower income countries.

Statistical analysis

Descriptive statistics were used to summarize the distribution of selected background characteristics of respondents. Categorical variables were summarised using frequencies with their associated percentages. Further analyses were conducted to examine individual and household-level factors that might be significantly associated with asthma and explored unobserved household level effects on the outcome. Single level and multilevel (mixed effects) binary logistic regression models were applied on 4621 individuals residing in 3970 households with complete measurements on asthma variable as well as complete measurements on potential explanatory variables considered in the final models. The extension of the single level binary logistic regression model to the multilevel logistic regression model is warranted because of the hierarchical structure of the SAGE dataset where we have individuals nested within households. Specifically, we applied random intercept multilevel logistic regression models to examine possible differences in asthma among individuals across households while simultaneously identifying potential risk factors. Thus, the multilevel modelling approach [35] placed particular emphasis on household level differences in the risk of asthma among individuals and the extent of nesting of asthma within a household which cannot be achieved through a single level logistic regression model.

The household-level Variance Partition Coefficient (VPC) [36] which measures the amount of variation in asthma among individuals from the random intercept multilevel logistic regression model is given by VPC = (household-level variance/ (household-level variance + individual-level variance)). Using the random intercept multilevel logistic regression, this quantity also coincides with the Intra-household Correlation Coefficient (ICC) which measures similarity in asthma episodes among individuals belonging to the same household. The individual-level residual is assumed to follow a standard logistic distribution with mean zero and variance π2 /3, where π = 3.14 [37].

Model parameters were obtained using maximum likelihood. Identity covariance structure provided a good fit to the data in the random intercept multilevel logistic model. The goodness of fit for the fitted models was examined using a likelihood ratio test (LRT), Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). Variance inflation factor (VIF) was used to check multicollinearity, and a VIF value below 10 was considered acceptable [38]. All the analyses were performed using STATA Version 14 [39]. P-value <0.20 on a univariable logistic regression was considered to select candidate set of risk factors for multivariable logistic regression analysis. P-value < 0.05 was used to declare statistical significance.

Ethical approval and consent to participate

SAGE was approved by the World Health Organization's Ethical Review Board (reference number RPC149) and the Ethical and Protocol Review Committee, College of Health Sciences, University of Ghana, Accra, Ghana. Written informed consent was obtained from all study respondents. All methods were performed in accordance with the relevant guidelines and regulations.

Patients and public involvement statement

The questionnaire used for the SAGE Wave 2 was modified from that of SAGE Wave 1 due to patient experiences and priority lessons learnt. The design of SAGE Wave 2 was informed by the involvement of patients in Wave 1, modifications made were based on patient priorities. Recruitment of patients and conduct of the study was by the WHO SAGE Ghana Team. The WHO SAGE Ghana Team organizes national stakeholders meeting to disseminate the findings of the national survey. A report of the national survey based on all data collected is provided to the general public and available on the WHO SAGE website.

Results

Sample characteristics

Out of the 4670 individual respondents, 102 (2.2%) reported an asthma diagnosis. Among those aged 50 years or older, 85 (2.4%) had asthma and 1.5% among those aged 18–49 years. A majority (75.5%) of respondents were 50 years and older while 2745 (58.8%) of respondents were female. Among the participants residing in rural and urban communities, 53 (1.1%) and 49(1.1%) respectively had asthma. Majority (53.6%) of households use wood as cooking fuel. A total of 283 (6.1%) of the respondents ever smoked tobacco or used smokeless tobacco. Over 48% of the respondents were Akan, with the Guan ethnicity in the minority (4.1%). Fifty-six percent reported being currently married and 74% had fathers with no formal education. Over 97% reported following some form of religion. Household characteristics included durable material for walls (62.8%), non-flush toilets (84.4%), shared toilets (76.6%) and hard floor (86.4%) (Table 1).

Table 1. Distribution (n, %) of selected background characteristics of respondents.

Characteristics n(%) Had asthma No asthma
n (%) n (%)
All ages - 102(2.18) 4568(97.82)
Aged ≥ 50 years 3575(75.50) 85(2.41) 3448(97.59)
Aged 18–49 years 1160(24.50) 17(1.50) 1120(98.50)
Place of residence
Rural 3346(57.74) 53(1.13) 2695(57.71)
Urban 2449(42.26) 49(1.05) 1873(40.11)
Cooking fuel
Gas/electric 642(11.91) 14(0.30) 540(11.69)
Coal/charcoal/kerosene 1861(34.53) 41(0.89) 1558(33.72)
Wood 2887(53.56) 45(0.97) 2423(52.43)
Sex
Male 1925(41.22) 41(0.88) 1884(40.34)
Female 2745(58.78) 61(1.31) 2684(57.47)
Ever smoked tobacco or used smokeless tobacco
Yes 283(6.06) 8(0.17) 275(5.89)
No 4388(93.94) 94(2.01) 4293(91.93)
Ethnicity
Akan 2265(48.50) 55(1.18) 2210(47.32)
Ewe 272(5.82) 4(0.09) 268(5.74)
Ga-Adangbe 583(12.48) 23(0.49) 560(11.99)
Guan 192(4.11) 1(0.02) 191(4.09)
Northern dialect 1358(29.08) 19(0.41) 1339(28.67)
Marital status
Never married 425(9.10) 6(0.13) 419(8.97)
Currently married 2597(55.61) 50(1.07) 2547(54.54)
Cohabiting 64(1.37) 0(0) 64(1.37)
Separated/divorced 525(11.24) 17(0.36) 508(10.88)
Widowed 1059(22.68) 29(0.62) 1030(22.06)
Educational status
No formal education 3459(74.07) 81(1.73) 3378(72.33)
Primary or less 570(12.20) 6(0.13) 564(12.08)
Secondary or higher 641(13.73) 15(0.32) 626(13.40)
Religion
Some religion 4541(97.24) 93(1.99) 4448(95.25)
No religion 129(2.76) 9(0.19) 120(2.57)
Wall type
Durable material 2917(62.81) 68(1.46) 2849(61.35)
Non-durable material 1727(37.19) 33(0.71) 1694(36.48)
Source of drinking water
Piped 2337(50.32) 49(1.06) 2288(49.27)
Non-piped 2307(49.68) 52(1.12) 2255(48.56)
Toilet facilities
Flush toilets 722(15.57) 23(0.50) 699(15.08)
Non-flush toilets 3914(84.43) 78(1.68) 3836(82.74)
Shared toilet
Yes 3003(76.55) 67(1.71) 2936(74.84)
No 920(23.45) 24(0.61) 896(22.84)
Floor
Hard floor 4006(86.39) 90(1.94) 3916(84.45)
Earth floor 631(13.61) 11(0.24) 620(13.37)

Univariable analyses

The results of univariable (unadjusted) analyses are presented in Table 2. Significant risk factors in the unadjusted model were age, ethnicity, religion, present health state, difficulty with self-care, source of drinking water and type of toilet facility in households. Those aged 60–69 (OR = 5.22, 95% CI: 1.24, 21.95) and 70 or more (OR = 5.56, 95% CI: 1.33, 23.26) years had increased odds of having asthma compared to those aged 18–29 years. Ga-Adangbe respondents (OR = 1.65, 95% CI: 1.01, 2.71) had higher odds of having asthma compared to their counterparts who are Akan while those with Northern dialect had lower odds of having asthma compared to those who are Akan. Those with no religion (OR = 3.59, 95% CI: 1.77, 7.28) had increased odds of having asthma compared to those with some religion. Respondents who rated themselves as having moderate (OR = 1.76, 95% CI: 1.13, 2.75) and bad/very bad (OR = 2.75, 95% CI: 1.58, 4.80) health state had increased odds of having asthma compared to those who rated themselves as good/very good. Those who rated their difficulty with self-care as severe/extreme (OR = 3.49, 95% CI: 1.23, 9.88) had increased odds of having asthma compared to those who rated themselves as none (i.e. no difficulty). Those residing in households with non-flush toilet facility (OR = 0.62, 95% CI: 0.39, 0.99) had lower odds of having asthma compared to those with flush toilets. We did not find marital status, sex, father’s educational status, household wall type, cooking fuel, shared toilets and floor types significantly associated with asthma episodes.

Table 2. Odds ratio for asthma: Single-level and multilevel binary logistic regression models.

  Univariable model Multivariable model Multilevel model
Characteristics UOR (95% CI) P-value AOR (95% CI) P-value AOR (95% CI) P-value
Age 0.073
18–29 ref ref ref
30–39 4.01(0.83–19.44) 0.085 3.91(0.77–19.8) 0.1 4.32(0.77–24.15) 0.096
40–49 3.47(0.73–16.42) 0.117 3.37(0.7–16.32) 0.131 3.72(0.7–19.77) 0.123
50–59 3.1(0.72–13.27) 0.128 2.93(0.66–12.96) 0.156 3.19(0.67–15.25) 0.147
60–69 5.22(1.24–21.95) 0.024* 4.49(1.03–19.55) 0.045* 5.06(1.06–24.07) 0.042*
70 or more 5.56(1.33–23.26) 0.019* 3.83(0.87–16.98) 0.077 4.32(0.89–20.93) 0.069
Ethnicity 0.005**
Akan ref ref ref
Ewe 0.6(0.22–1.67) 0.327 0.56(0.2–1.58) 0.273 0.53(0.17–1.64) 0.267
Ga-Adangbe 1.65(1.01–2.71) 0.047* 1.53(0.91–2.57) 0.112 1.63(0.89–2.98) 0.116
Guan 0.21(0.03–1.53) 0.123 0.25(0.03–1.84) 0.173 0.24(0.03–1.89) 0.174
Northern dialect 0.57(0.34–0.96) 0.036* 0.67(0.39–1.16) 0.151 0.65(0.35–1.19) 0.162
Marital status 0.177
Never married ref ref ref
Currently married 0.76(0.52–1.13) 0.177 0.85(0.56–1.28) 0.432 0.84(0.53–1.34) 0.471
Sex 0.832 - -
Male ref - -
Female 1.04(0.7–1.56) 0.832 - -
Father’s educational status 0.158 - -
No formal education ref ref ref
Primary or less 0.44(0.19–1.02) 0.056 0.4(0.17–0.94) 0.036* 0.38(0.15–0.95) 0.039*
Secondary or higher 1(0.57–1.75) 0.998 0.99(0.54–1.82) 0.971 1.01(0.51–2) 0.984
Religion <0.001***
Some religion ref ref ref
No religion 3.59(1.77–7.28) <0.001*** 2.52(1.18–5.41) 0.017* 2.93(1.15–7.47) 0.024*
Health state 0.001**
Good/very good ref ref ref
Moderate 1.76(1.13–2.75) 0.013* 1.43(0.88–2.31) 0.147 1.46(0.85–2.5) 0.169
Bad/very bad 2.75(1.58–4.8) <0.001*** 1.93(0.99–3.76) 0.052 1.97(0.92–4.21) 0.079
Self-care 0.049*
None ref ref ref
Mild 0.67(0.35–1.3) 0.234 0.6(0.3–1.23) 0.165 0.56(0.26–1.23) 0.148
Moderate 1.35(0.58–3.13) 0.486 0.94(0.38–2.32) 0.895 0.91(0.32–2.54) 0.855
Severe/extreme 3.49(1.23–9.88) 0.019* 2.03(0.64–6.43) 0.23 2.18(0.54–8.88) 0.275
Wall 0.343 - -
Durable material ref - -
Non-durable material 0.82(0.54–1.24) 0.343 - -
Source of drinking water 0.713 - -
Piped ref - -
Non-piped 1.08(0.73–1.6) 0.713 - -
Toilet facilities 0.046* - -
Flush toilets ref ref ref
Non-flush toilets 0.62(0.39–0.99) 0.046* 0.58(0.35–0.96) 0.033* 0.55(0.31–0.98) 0.041*
Cooking fuel 0.237
Gas/electricity ref - -
Coal/charcoal/kerosene 1.02(0.55–1.88) 0.962 - -
Wood 0.72(0.39–1.31) 0.281 - -
Shared toilet 0.506 - -
Yes ref - -
No 1.17(0.73–1.88) 0.506 - -
Floor 0.422 - -
Hard floor ref - -
Earth floor 0.77(0.41–1.45) 0.422 - -

UOR: unadjusted odds ratio, AOR: adjusted odds ratio, CI: confidence interval, ref: reference category

*: p-value<0.05

**: p-value<0.01

***: p-value<0.001.

Multivariable analyses

In the multivariable (adjusted) analyses only age, father’s education, religion and type of household toilet facilities were significantly associated with asthma episodes. The odds of having asthma was higher among those aged 60–69 (OR = 4.49, 95% CI: 1.03, 19.55) years compared to those aged 18–29 years. Having a father with primary education or less (OR = 0.40, 95% CI: 0.17, 0.94) decreased the odds of having asthma compared to those with no formal education. Having no religion (OR = 2.52, 95% CI: 1.18, 5.41) increased the odds of having asthma compared to those with some religion. Residing in households with non-flush toilet facility (OR = 0.58, 95% CI: 0.35, 0.96) lower the odds of having asthma compared to those with flush toilets (Table 2).

Multilevel analyses

We extended the single level multivariable model to a multilevel model (Tables 2 and 3). This accounted for the clustering of individuals within the same households. Results from the multilevel showed that only age, father’s education, religion and type of household toilet facilities were significantly associated with asthma. Though similar findings were observed in the models, their effect sizes were different. In the multilevel model, the odds of having asthma was higher among those aged 60–69 (OR = 5.06, 95% CI: 1.06, 24.07) years compared to those aged 18–29 years. Having a father with primary education or less (OR = 0.38, 95% CI: 0.15, 0.95) decreased the odds of having asthma compared to those with no formal education. Having no religion (OR = 2.93, 95% CI: 1.15, 7.47) increased the odds of having asthma compared to those with some religion. Residing in households with non-flush toilet facility (OR = 0.55, 95% CI: 0.31, 0.98) lower the odds of having asthma compared to those with flush toilets (Table 2).

Table 3. Variance component analysis from the multilevel binary logistic regression model.

Variance components Estimate 95% confidence interval Intraclass correlation Coefficient (ICC)
Individual level (IL) 3.29 - -
Household level (HL) 2.22 0.55, 9.04 HL/(HL+IL)*100 = 40.29%

Comparing the single level multivariable model to the multilevel model, we observed a p-value of 0.0477 which is below 0.05, suggesting that the multilevel model provided a good fit to the data. Thus, the multilevel model was preferred among the competing models suggesting strong household-level variation in asthma.

The variance partition coefficients (VPC) which coincides with the intra-class correlation coefficient (ICC) is presented in Table 3. The results showed that over 40% of variance in asthma episodes could be attributable to residual household-level variations after adjusting for individual and household level factors in our model.

Discussion

The prevalence of asthma from a nationally representative study among those aged 18 years and older for the period under study (2014–2015) was 2.2%, with a prevalence of 2.4% among adults aged ≥50 years and 1.5% among those aged 18–49 years. The odds of having asthma was highest in the 60–69 year age group in the adjusted models. Protective factors were having a father with some form of education at the primary level or less and possession of a non-flush toilet.

The present study found the asthma prevalence rate among older adults was consistent with a multi-site study conducted earlier (2007–2010) [40], but lower than corresponding rates reported in independent surveys conducted in other African countries: 2.7% in Cameroon (≥19 years) [7], 4.3% in Gambia (≥15 years) [8], 5.3% in Botswana (10–64 years) [9], 6.5% in Tunisia (2–52 years) [10], 6.8% in Uganda (≥35 years) [11], 6.9% in Kinshasa (≥18 years) [12] and 15.2% in Nigeria (18–65 years) [13]. The asthma prevalence rate in the present study is also lower than has been reported in United States, 7.7% (≥ 18 years) [41] and 7.2% in Israel (≥21 years) [42], but it exceeds the asthma prevalence rate of 1.24% reported in China (≥14 years) [31]. The prevalence rates of 1.50%, 2.20% and 2.40%, respectively for those aged 18–49, ≥18 and ≥50 years reported in the present study was also lower than 3.65% (doctor-diagnosed asthma) and 3.77% (treated asthma) reported for Ghana in the World Health Survey, 2002 and 2003. The survey involved 70 of the 192 WHO member states, but participants were limited to adults aged 18-45years, which may contribute to the differences observed [43]. Notwithstanding the low prevalence rate estimated for asthma in the study population, the projected increase in the population of older adults underscores the need to ensure that exposure to modifiable risk factors are minimized.

These differences could be attributed to methodological differences (for example: definition of asthma and/or ascertainment of asthma cases by self-report, physician diagnosed or algorithm-based; whether or not a nationally representative sample was used) and differences in environmental exposures. For instance, an earlier multi-site study conducted in six low- and middle-income countries (China, Ghana, India, Mexico, Russia and South Africa) to determine the prevalence of NCDs found that for all six conditions (angina, arthritis, asthma, chronic lung disease, depression and hypertension), the algorithm/measured test prevalence was higher than self-reported prevalence of NCDs. Variations in asthma prevalence rates have been attributed to environmental exposures including microorganisms, pollutants, allergens and diet which influence the disease expression in susceptible persons [44].

Individuals in the age group 60–69 years demonstrated a five-fold increase in odds of having asthma episodes (OR = 5.06, 95% CI: 1.06, 24.07) compared to individuals in the youngest age group, 18–29 years. Furthermore, a study conducted in China among adults ≥15 years, the highest prevalence (114/2809; 4.06%) was reported among adults aged ≥60 years [23]. A multi-centre study in India demonstrated increased odds of having asthma with increasing age [45], however the present study showed a decline in odds from 18–59 years and increased in the age group 60–69 years, reaching statistical significance. This finding is further supported by a study in North Africa which reported that asthma prevalence rates were highest at extremes of age. Peak prevalence rates were reported in children below the age of 16 years and in adults >54 years in Algeria and among adults aged >54 years in Tunisia [14].

The relationship between religion and asthma is uncertain. Rather it has been used to explain self-management behaviours, medication adherence and has been perceived as a coping strategy in asthma where studies have demonstrated either a potentially positive influence [46, 47] or a negative effect [48]. The positive influence of religion on individual health appears to be mediated through provision of social ties and support, access to the social capital of religious groups, enhancing health promoting behaviours and positive emotions [4951]. Consequently, the absence of religious affiliation or involvement may foster an environment that impacts negatively on health (for example, smoking and lack of physical activity) particularly in older adults. This might predispose to the expression of asthmatic phenotypes, where there is genetic disposition, atopy and exposure to environmental triggers. The nearly three-fold increase in odds of having asthma calls for further investigation to explain the mechanism underlying this finding.

Having a father with primary education or less as the highest level of education (compared to no formal education) had a protective effect in the present study. The influence of paternal education on asthma in adults is unclear. An educated parent is more aware of and better able to understand the disease, recognize its symptoms and support its daily management [52]. This would include among others, access to appropriate healthcare. Education further motivates the avoidance of health risks [53] such as exposure to environmental agents that trigger attacks. Education also erodes traditional beliefs regarding the causes of diseases as being due to spiritual forces, their agents or ancestors which often results in the patronage of prayer camps or alternative providers believed to have a cure for all kinds of diseases [54]. Lack of formal education is often closely linked to a low socioeconomic status which predisposes individuals to adverse conditions often injurious to health. This is particularly important in older adults as the biological process of aging has been associated with increased vulnerability to sickness and limited mobility [55].

Individuals reporting the use of non-flush toilets in households were 56% less likely to have asthma episodes [OR = 0.44, 95%CI 0.31, 0.98] compared to flush toilets and therefore this was a protective factor. Flush toilets tend to produce aerosols in substantial quantities when flushed. Some of these aerosols, containing microbes, desiccate to become droplet nuclei above the toilet within 5 minutes and up to 90 minutes post-flush, with the toilet seat raised [56]. They are carried in air currents as viable forms small enough to get translocated through the nasal passages during inhalation. Exposure of respiratory epithelia to microbes stimulate the antigen presenting cells to induce an immune response consistent with inflammation characterized by increased eosinophils, basophils, and T helper 2 cells. Furthermore, breaches in epithelial integrity and inability of the macrophages to clear microbes in the airways may propagate inflammatory responses [57]. These protective mechanisms in the lungs may decline with age. Non-flush toilets are less likely to generate aerosols, unlike flush toilets that generate aerosols per flush. The ability to cause infection depends on the ability of the pathogen to survive environmental conditions, the number of organisms inhaled, their virulence and the immune status of the host. Available evidence suggests the potential for airborne transmission of norovirus, Severe Acute Respiratory Syndrome (SARS) coronavirus and influenza, since these can be shed in faeces and vomit which is often disposed of in toilets [56]. Infections of the respiratory tract such as influenza can trigger asthmatic episodes in predisposed persons. The toilet is one of the areas in the built environment that contributes to the microbiome to which a susceptible adult can be exposed. Ethnicity, present health state, difficulty with self-care and source of drinking water did not achieve statistical significance in the multivariable and multilevel analysis.

The results make a strong case for ensuring universal access to education up to at least a primary level as currently implemented is sustained to inform healthy choices and ensure progress in meeting Sustainable Development Goals. Ensuring that flush toilets are either flushed with seats closed or non-flush options are available options to households with older adults should be driven by the Ministry of Health through advocacy and implemented at district level. Intersectoral collaboration with the Ministry of Water and Sanitation, Ministry of Local Government and Rural Development, Environmental Protection Agency, Ministry of Finance and relevant development partners will be required for implementation. Religious affiliation and involvement in religious activity should be promoted to harness potential benefits for support to older adults. Religious bodies can extend outreach services to older adults through home visits either independently or as an integrated service with healthcare facilities.

The strengths of the present study include: the use of a nationally representative sample selected by probability based multi-stage sampling which allows generalization of the results. Furthermore, a standardized questionnaire used in the study also permits the comparability of results across countries in the study. The use of multilevel modelling approach controlled for the effect of clustering in households, resulting in an unbiased standard error of the estimates which will help avoid spurious significant risk factors considered in the model. Also, combining individual and household-level data allows identification of both individual and household level factors that might influence the outcome. The limitations in the study include the use of self-report, however the discomforting nature of the symptoms make it unlikely to be missed by the affected individual and a combination of other methods of ascertainment might have yielded additional cases. The nature of our data and the modelling approach did not allow for drawing causation effects. The use of p<0.2 as the stopping rule to identify candidate set of covariates in the bivariate model to be included in the multivariable model might not provide optimal variable selection for the covariates, although previous studies have provided a strong recommendation for using p-values in the range of 0.15–0.20 [58] as used in our study. One major challenge in asthma epidemiologic studies in developing countries is the extent of asthma control and proper asthma management including asthma controller treatment availability, compliance to treatment, comorbidities, and impact on quality of life. A previous study in Ghana has reported daily asthma symptom occurrence of 11.7%, reliever medication rates were estimated as 18.2%, with regular use at 56.5% among the 77 asthmatic patients involved [59].

Conclusion

Risk factors associated with asthma episodes among adults in Ghana were being aged within 60–69 years and absence of religious affiliation. Level of father’s education with primary or less as the highest level and having a non-flush toilet were protective factors. Ethnicity, present health state, difficulty with self-care and source of drinking water were not significantly independently related to asthmatic episodes in this study.

Overall, individual as well as household factors were seen to influence the prevalence of asthma in this national survey. Clinical management of these patients in health facilities should consider household factors in addition to individual level factors. In addition, national efforts in promoting dry sanitation systems and appropriate use of flush systems to minimize aerosol dispersion for the citizenry is worth considering.

Acknowledgments

We are grateful to the World Health Organization and her partners who made the SAGE study possible and provided us with the data at no cost. We are also thankful to all respondents and interviewers who participated in the SAGE survey in Ghana. The Ministry of Health, Ghana, is supportive of SAGE. The University of Ghana’s Department of Community Health contributed training facilities, data entry support, and storage of materials. The Ghana Statistical Service provided the sampling information for the sampling frame and updates.

Data Availability

Data is freely available upon making official request to WHO SAGE Team through the WHO website at http://www.who.int/healthinfo/sage/cohorts/en/. The data is provided to researchers freely but the WHO SAGE Team only releases the data to researchers upon request made directly to WHO, and individual researchers granted permission to use the data are not allowed to make the data (in any form) available to third parties. Any third party interested in the data must apply directly to the WHO SAGE Team.

Funding Statement

Funding was obtained for the main WHO SAGE Wave 2 Survey in Ghana with financial support provided by the US National Institute on Aging through Interagency Agreements (OGHA 04034785; YA1323-08-CN-0020; Y1-AG-1005-01) with the World Health Organization and a Research Project Grant (R01 AG034479- 64401A1). The funder provided support in the form of salaries for authors [RB, AEY], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. However, the work in this study did not receive any funding support. Also, Deloitte Consulting, West Africa Deloitte & Touche did not provide any financial support for the study and played no role in the study”.

References

  • 1.Collaborators GCRD: Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 2020, 8(6):585–596. 10.1016/S2213-2600(20)30105-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.GBD 2015. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respiratory Medicine. 2017;5(9): 691–706. 10.1016/S2213-2600(17)30293-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Maselli DJ, Hanania NA. Asthma COPD overlap: Impact of associated comorbidities. Pulm Pharmacol Ther. 2018; 52:27–31. 10.1016/j.pupt.2018.08.006 [DOI] [PubMed] [Google Scholar]
  • 4.Zemedkun K, Woldemichael K, Tefera G. Assessing control of asthma in Jush, Jimma, south west Ethiopia. Ethiopian Journal of Health Sciences. 2014;24(1):49–58. 10.4314/ejhs.v24i1.7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Amoah AS, Forson AG, Boakye DA. A review of epidemiological studies of asthma in Ghana. Ghana Medical Journal. 2012;46(2):23–8. [PMC free article] [PubMed] [Google Scholar]
  • 6.Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: Update 2015. Available at http://www.ginasthma.com cited 29th December, 2018.
  • 7.Pefura-Yone EW, Kengne AP, Balkissou AD, et al. Prevalence of asthma and allergic rhinitis among adults in Yaounde, Cameroon. PLoS One. 2015;10(4): e0123099 10.1371/journal.pone.0123099 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Walraven GE, Nyan OA, Van Der Sande MA, et al. Asthma, smoking and chronic cough in rural and urban adult communities in The Gambia. Clinical & Experimental Allergy. 2001;31(11):1679–85. 10.1046/j.1365-2222.2001.01094.x [DOI] [PubMed] [Google Scholar]
  • 9.Letamo G, Keetile M, Navaneetham K, et al. Prevalence and correlates of self-reported chronic non-communicable diseases in Botswana: a cross-sectional study. International Health. 2017;9(1):11–9. 10.1093/inthealth/ihw052 [DOI] [PubMed] [Google Scholar]
  • 10.Sonia T, Meriem M, Yacine O, et al. Prevalence of asthma and rhinitis in a Tunisian population. The Clinical Respiratory Journal. 2018;12(2):608–15. 10.1111/crj.12570 [DOI] [PubMed] [Google Scholar]
  • 11.Morgan BW, Siddharthan T, Grigsby MR, et al. Asthma and Allergic Disorders in Uganda: A Population-Based Study Across Urban and Rural Settings. J Allergy Clin Immunol Pract. 2018; 6(5):1580–7. 10.1016/j.jaip.2017.11.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Obel KB, Ntumba KJ, Kalambayi KP, et al. Prevalence and determinants of asthma in adults in Kinshasa. PloS ONE. 2017;12(5):e0176875 10.1371/journal.pone.0176875 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Desalu OO, Oluboyo PO, Salami AK. The prevalence of bronchial asthma among adults in Ilorin, Nigeria. Afr J Med Med Sci. 2009;38(2):149–54. [PubMed] [Google Scholar]
  • 14.Nafti S, Taright S, El Ftouh M, et al. Prevalence of asthma in North Africa: the Asthma Insights and Reality in the Maghreb (AIRMAG) study. Respiratory Medicine. 2009;103: S2–11. 10.1016/S0954-6111(09)70022-8 [DOI] [PubMed] [Google Scholar]
  • 15.Urbstonaitis R, Deshpande M, Arnoldi J. Asthma and health related quality of life in late midlife adults. Research in Social and Administrative Pharmacy. 2019;15(1):61–9. 10.1016/j.sapharm.2018.03.003 [DOI] [PubMed] [Google Scholar]
  • 16.Calys-Tagoe BN, Hewlett SA, Dako-Gyeke P, Yawson AE, Baddoo NA, Seneadza NA, et al. : Predictors of subjective well-being among older Ghanaians. Ghana Med J 2014, 48(4):178–184. 10.4314/gmj.v48i4.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wjst M, Boakye D. Asthma in Africa. PLoS Medicine. 2007;4(2): e72 10.1371/journal.pmed.0040072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Addo-Yobo EO, Custovic A, Taggart SC, et al. Risk factors for asthma in urban Ghana. J Allergy Clinical Immunol. 2001;108(3):363–8. 10.1067/mai.2001.117464 [DOI] [PubMed] [Google Scholar]
  • 19.Kumar R. Prenatal factors and the development of asthma. Curr Opin Pediatr. 2008;20(6):682–7. 10.1097/MOP.0b013e3283154f26 [DOI] [PubMed] [Google Scholar]
  • 20.Sin DD, Sutherland ER. Obesity and the lung: 4· Obesity and asthma. Thorax. 2008;63(11):1018–23. 10.1136/thx.2007.086819 [DOI] [PubMed] [Google Scholar]
  • 21.Goldberg S, Israeli E, Schwartz S, et al. Asthma prevalence, family size, and birth order. Chest. 2007;131(6):1747–52. 10.1378/chest.06-2818 [DOI] [PubMed] [Google Scholar]
  • 22.Subbarao P, Mandhane PJ, Sears MR. Asthma: epidemiology, etiology and risk factors. CMAJ. 2009;181(9): E181–90. 10.1503/cmaj.080612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Fu QL, Du Y, Xu G, et al. Prevalence and occupational and environmental risk factors of self-reported asthma: evidence from a cross-sectional survey in seven Chinese cities. Int J Environ Res Public Health. 2016;13(11):1084 10.3390/ijerph13111084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Devereux G, Seaton A. Diet as a risk factor for atopy and asthma. J Allergy Clin Immunol. 2005;115(6):1109–17. 10.1016/j.jaci.2004.12.1139 [DOI] [PubMed] [Google Scholar]
  • 25.Allen S, Britton J, Leonardi-Bee J. Association between antioxidant vitamins and asthma outcomes: Systematic review and meta-analysis. Thorax. 2009;64(7):610–9. 10.1136/thx.2008.101469 [DOI] [PubMed] [Google Scholar]
  • 26.Bryant-Stephens T. Asthma disparities in urban environments. J Allergy Clin Immunol. 2009;123(6):1199–206. 10.1016/j.jaci.2009.04.030 [DOI] [PubMed] [Google Scholar]
  • 27.Jie Y, Isa ZM, Jie X, et al. Urban vs. rural factors that affect adult asthma In: Reviews of Environmental Contamination and Toxicology. 2013;226:33–63. Springer, New York, NY: 10.1007/978-1-4614-6898-1_2 [DOI] [PubMed] [Google Scholar]
  • 28.Wang CS, Wang J, Zhang X, et al. Is the consumption of fast foods associated with asthma or other allergic diseases? Respirology. 2018;23(10):901–13. 10.1111/resp.13339 [DOI] [PubMed] [Google Scholar]
  • 29.Nkosi V, Wichmann J, Voyi K. Chronic respiratory disease among the elderly in South Africa: any association with proximity to mine dumps? Environ Health. 2015;14(1):33 10.1186/s12940-015-0018-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Petronella SA, Conboy-Ellis K. Asthma epidemiology: risk factors, case finding, and the role of asthma coalitions. Nurs Clin North Am. 2003; 38(4):725–35. 10.1016/s0029-6465(03)00099-9 [DOI] [PubMed] [Google Scholar]
  • 31.Lin J, Wang W, Chen P, et al. Prevalence and risk factors of asthma in mainland China: The CARE study. Respiratory Medicine. 2018;137:48–54. 10.1016/j.rmed.2018.02.010 [DOI] [PubMed] [Google Scholar]
  • 32.Ayaaba E, Li Y, Yuan J, et al. Occupational Respiratory Diseases of Miners from Two Gold Mines in Ghana. Int J Environ Res Public Health. 2017;14(3):337 10.3390/ijerph14030337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Stevens W, Addo‐Yobo E, Roper J, et al. Differences in both prevalence and titre of specific immunoglobulin E among children with asthma in affluent and poor communities within a large town in Ghana. Clinical & Experimental Allergy. 2011;41(11):1587–94. 10.1111/j.1365-2222.2011.03832.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Charlton K, Ware LJ, Menyanu E, et al. Leveraging ongoing research to evaluate the health impacts of South Africa's salt reduction strategy: a prospective nested cohort within the WHO-SAGE multicountry, longitudinal study. BMJ Open. 2016; 6(11):e013316 10.1136/bmjopen-2016-013316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Goldstein H: Multilevel Statistical Models, 3rd edn. London: Arnold; 2003. [Google Scholar]
  • 36.Steele F, Goldstein H, Rao C, Sinharay S: Multilevel Models in Psychometrics. Psychometrics 2007;26:401–420. [Google Scholar]
  • 37.Hedeker D, Gibbons RD: MIXOR: a computer program for mixed-effects ordinal regression analysis. Comput Methods Programs Biomed 1996;49(2):157–76. 10.1016/0169-2607(96)01720-8 [DOI] [PubMed] [Google Scholar]
  • 38.Hair JFJ, Anderson RE, Tatham RL, et al. Multivariate Data Analysis. 3rd edn New York: Macmillan; 1995. [Google Scholar]
  • 39.StataCorp: Stata Statistical Software: Release 14. In. College Station, TX: StataCorp LP; 2015. [Google Scholar]
  • 40.Arokiasamy P, Kowal P, Capistrant BD, et al. Chronic noncommunicable diseases in 6 low-and middle-income countries: Findings from Wave 1 of the World Health Organization's Study on global AGEing and adult health (SAGE). Am J Epidemiol. 2017;185(6):414–28. 10.1093/aje/kww125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Akinbami LJ, Bailey CM, Johnson CA, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS Data Brief. 2012. May;(94):1–8. [PubMed] [Google Scholar]
  • 42.Hayek S, Ifrah A, Enav T, et al. Prevalence, Correlates, and Time Trends of Multiple Chronic Conditions Among Israeli Adults: Estimates from the Israeli National Health Interview Survey, 2014–2015. Prev Chronic Dis. 2017;14: E64 10.5888/pcd14.170038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12(1):204 10.1186/1471-2458-12-204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Braman SS. The global burden of asthma. Chest. 2006;130(1):4S–12S. [DOI] [PubMed] [Google Scholar]
  • 45.Aggarwal AN, Chaudhry K, Chhabra SK, et al. Prevalence and risk factors for bronchial asthma in Indian adults: a multicentre study. Indian Journal of Chest Diseases and Allied Sciences. 2006;48(1):13 [PubMed] [Google Scholar]
  • 46.Druedahl L, Yaqub D, Nørgaard L, et al. Young Muslim Women Living with Asthma in Denmark: A Link between Religion and Self-Efficacy. Pharmacy. 2018;6(3):73 10.3390/pharmacy6030073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Cotton S, Weekes JC, McGrady ME, et al. Spirituality and religiosity in urban adolescents with asthma. J Relig Health. 2012;51(1):118–31. 10.1007/s10943-010-9408-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Ahmedani BK, Peterson EL, Wells KE, et al. Asthma medication adherence: the role of God and other health locus of control factors. Ann Allergy Asthma Immunol. 2013;110(2):75–9. 10.1016/j.anai.2012.11.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Idler E. Religion: The invisible social determinant. Religion as a social determinant of public health. 2014:1–23. [Google Scholar]
  • 50.Harvey IS, Silverman M. The role of spirituality in the self-management of chronic illness among older African and Whites. J Cross Cult Gerontol. 2007;22(2):205–20. 10.1007/s10823-007-9038-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Koenig HG. Religion, spirituality, and health: The research and clinical implications. ISRN Psychiatry. 2012:278730 10.5402/2012/278730 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Leung R, Wong G, Lau J, et al. Prevalence of asthma and allergy in Hong Kong schoolchildren: an ISAAC study. Eur Respir J. 1997;10(2):354–60. 10.1183/09031936.97.10020354 [DOI] [PubMed] [Google Scholar]
  • 53.Hahn RA, Truman BI. Education improves public health and promotes health equity. Int J Health Serv. 2015;45(4):657–78. 10.1177/0020731415585986 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Badasu DM, Abuosi AA, Adzei FA, et al. Educational status and beliefs regarding non-communicable diseases among children in Ghana. BMC Public Health. 2018;18(1):313 10.1186/s12889-018-5211-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Abalo EM, Mensah CM, Agyemang-Duah W, et al. Geographical Differences in Perceived Health Status Among Older Adults in Ghana: Do Gender and Educational Status Matter? Gerontology and Geriatric Medicine. 2018;4:2333721418796663 10.1177/2333721418796663 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Johnson DL, Mead KR, Lynch RA, Hirst DV. Lifting the lid on toilet plume aerosol: a literature review with suggestions for future research. Am J Infect Control. 2013;41(3):254–8. 10.1016/j.ajic.2012.04.330 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Sullivan A, Hunt E, MacSharry J, Murphy DM. The microbiome and the pathophysiology of asthma. Respir Res. 2016;17(1):163 10.1186/s12931-016-0479-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression. New York: John Wiley & Sons, Incorporated, 2013. [Google Scholar]
  • 59.Anum PO, Anto BP, Forson AG: Structured pharmaceutical care improves the health- related quality of life of patients with asthma. J Pharm Policy Pract 2017, 10:8 10.1186/s40545-017-0097-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Florian Fischer

6 Aug 2020

PONE-D-20-10825

Prevalence, socio-demographic and environmental determinants of asthma in 4621 Ghanaian adults: Evidence from Wave 2 of the World Health Organization’s Study on global AGEing and adult health.

PLOS ONE

Dear Dr. Aheto,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please consider whether you are able and willing to incorporate the comment of Reviewer 2 on using wave 1 in addition for avoing the limitations of a cross-sectional study. The decision is up to you, but please comment on this issue why you decided to exclude ot take wave 1 into account.

Please submit your revised manuscript by Sep 20 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Florian Fischer

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"Financial support was provided by the US National Institute on Aging through

Interagency Agreements (OGHA 04034785; YA1323-08-CN-0020; Y1-AG-1005-01) with the

World Health Organization and a Research Project Grant (R01 AG034479- 64401A1). WHO

contributed financial and human resources to SAGE. The Ministry of Health, Ghana, is

supportive of SAGE. The University of Ghana’s Department of Community Health contributed

training facilities, data entry support, and storage of materials. The Ghana Statistical Office

provided the sampling information for the sampling frame and updates."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The authors received no specific funding for this work"

3. Thank you for stating the following in the Competing Interests section:

"The authors have declared that no competing interests exist."

We note that one or more of the authors are employed by a commercial company: 3Deloitte Consulting, West Africa Deloitte & Touche.

3.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

3.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. 

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I felt this was a well done study. The manuscript provides helpful information on Ghanaian health that contains actionable areas for future public health interventions. The addition of a) a map of Ghana, and b) more geographical context for from where within Ghana respondents live would strengthen the paper.

Reviewer #2: This is an exploratory study examining the prevalence, socio-demographic and environmental determinants of asthma in Ghana. My main concerns include 1) the cross-sectional design, 2) the lack of considerations of neighborhood-level risk factors, and 3) the variable selection procedure used. Below please find my detailed comments.

1. Page 3, background, reference 1: please update the reference and cite the most recent statistics from the global burden of disease study.

2. Page 5, study population: please briefly describe the sampling strategy used in SAGE.

3. Page 5, study population and outcome variable: since SAGE is a longitudinal study, it might be better to use data from both wave 1 and wave 2 to identify incident asthma cases. The current analsyes depending on the asthma question only from the wave 2 made this a cross-sectional study, which substantially limited the significance of this study.

4. Page 5, explanatory variables: as this is an exploratory study, it is unclear why the authors only included these variables. Why neighborhood-level factors were not included? Many established risk factors mentioned in the background section were not included.

5. Page 7, statistical analyses: the authors only included variables with a p-value<0.2 from the univariable regression model in the multivariable regression model. This variable selection approach is problematic. More advanced approach such as the elastic net model or Lasso model with hyperparameters determined by cross-validations should be used to perform the variable selection. e.g., the glmmLasso package in R can be used to implement Lasso for gelearized linear mixed models.

6. Page 15: one major limitation is the cross-sectional design of this study: the current exposures to the risk factors may not be representative of the historical exposures before the onset of asthma. This needs to be discussed in the limitation section. Again, if asthma data is available from wave 1, I highly recommend the authors to use the data to identify incident asthma cases to avoid the cross-sectional design of the study.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Dec 9;15(12):e0243642. doi: 10.1371/journal.pone.0243642.r002

Author response to Decision Letter 0


10 Sep 2020

Responses from the authors:

First, we extend our profound gratitude and thanks to the Editors and the Reviewers for their efforts and valuable comments on our paper.

We have given your comments the needed attention and action and are happy to resubmit the revised manuscript for your kind consideration and subsequent publication in your cherished journal, and together we can all help in addressing this serious public health challenge facing millions of people in most developing countries like Ghana.

Below are our responses to the comments in italics and you will also find the needed changes in the main report tracked in colour using the tracking facility in word. In addition, we have made few other changes to the paper with the sole aim of enhancing the understanding of our readers and these were also tracked in colour.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: we have revised the manuscript to address this (e.g. see the tittle page, abstract and the introduction, materials and methods).

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"Financial support was provided by the US National Institute on Aging through

Interagency Agreements (OGHA 04034785; YA1323-08-CN-0020; Y1-AG-1005-01) with the

World Health Organization and a Research Project Grant (R01 AG034479- 64401A1). WHO

contributed financial and human resources to SAGE. The Ministry of Health, Ghana, is

supportive of SAGE. The University of Ghana’s Department of Community Health contributed

training facilities, data entry support, and storage of materials. The Ghana Statistical Office

provided the sampling information for the sampling frame and updates."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The authors received no specific funding for this work"

Response: Thank you. The present study (the work in this manuscript) did not receive any funding. We were only acknowledging those who funded the original survey that generated the data which is serving as a secondary data for the present study. However, some of my co-authors were part of investigators during the main survey. We revised the manuscript by removing the funding statement under the acknowledgement section and also removed the ‘funding section’ from the manuscript (see lines 7-12, page 20).

The acknowledgement now reads “We are grateful to the World Health Organization and her partners who made the SAGE study possible and provided us with the data at no cost. We are also thankful to all respondents and interviewers who participated in the SAGE survey in Ghana. The Ministry of Health, Ghana, is supportive of SAGE. The University of Ghana’s Department of Community Health contributed training facilities, data entry support, and storage of materials. The Ghana Statistical Service provided the sampling information for the sampling frame and updates.”

For the online funding statement, the following can be used or you can modify it to suit the journal requirement: “Funding was obtained for the main WHO SAGE Wave 2 Survey in Ghana with financial support provided by the US National Institute on Aging through Interagency Agreements (OGHA 04034785; YA1323-08-CN-0020; Y1-AG-1005-01) with the World Health Organization and a Research Project Grant (R01 AG034479- 64401A1). The funder provided support in the form of salaries for authors [RB, AEY], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. However, the work in this study did not receive any funding support. Also, Deloitte Consulting, West Africa Deloitte & Touche did not provide any financial support for the study and played no role in the study”. See response to point 3 below:

3. Thank you for stating the following in the Competing Interests section:

"The authors have declared that no competing interests exist."

We note that one or more of the authors are employed by a commercial company: 3Deloitte Consulting, West Africa Deloitte & Touche.

Response: Thank you. Deloitte Consulting, West Africa Deloitte & Touche did not provide any financial support for the study and played no role in the study. Our co-author, Mr Kallson participated in this study in his capacity as an individual. Thus, he was not representing his company. We addressed this in our response to point 2 above.

3.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

Response: Thank you. The commercial affiliation did not play any role in the study. We have updated the funding (We addressed this in our response to point 2 above) and the author contribution statements (lines 13-16, page 19) to reflect the changes required.

We provided the following: “All authors except Mr Kallson declare that they have no conflict of interest. Though Mr Kallson was working with Deloitte Consulting, West Africa Deloitte & Touche at the time of the study, Deloitte Consulting did not provide any financial support for the study and did not play any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. Mr Kallson participated in this study in his capacity as an individual and was not acting on behalf of Deloitte Consulting, and this does not alter our adherence to PLOS ONE policies on sharing data and materials.”

3.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

Response: Thank you. We have provided the updated funding and competing interests statement in the cover letter as requested.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

Response: There is no legal restrictions on the data known to the authors. The data is provided to researchers freely but the WHO SAGE Team only releases the data to researchers upon request directly made to WHO, and individual researchers granted permission to use the data are not allowed to make the data (in any form) available to third parties. Any third party interested in the data must apply directly to the WHO SAGE Team. We have included this in the cover letter as requested, and also in the manuscript.

Under data availability, we inserted “Data is freely available upon making official request to WHO SAGE Team through the WHO website at http://www.who.int/healthinfo/sage/cohorts/en/. The data is provided to researchers freely but the WHO SAGE Team only releases the data to researchers upon request made directly to WHO, and individual researchers granted permission to use the data are not allowed to make the data (in any form) available to third parties. Any third party interested in the data must apply directly to the WHO SAGE Team”. See lines 1-2, page 19 and lines 1-4, page 20.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Response: Please, refer to our response to point 4(a) and also to the cover letter.

Reviewers' comments:

Reviewer #1: I felt this was a well done study. The manuscript provides helpful information on Ghanaian health that contains actionable areas for future public health interventions. The addition of a) a map of Ghana, and b) more geographical context for from where within Ghana respondents live would strengthen the paper.

Response: Thank you for the useful comment. Unfortunately, the survey did not collect data on spatial coordinates (latitude and longitude) of the participants in the 2014/2015 study. Our current study is based on this secondary data and it is therefore not possible to show the locations of these participants on the map of Ghana in the present study.

Reviewer #2: This is an exploratory study examining the prevalence, socio-demographic and environmental determinants of asthma in Ghana. My main concerns include 1) the cross-sectional design, 2) the lack of considerations of neighborhood-level risk factors, and 3) the variable selection procedure used. Below please find my detailed comments.

1. Page 3, background, reference 1: please update the reference and cite the most recent statistics from the global burden of disease study.

Response: Thank you. Revised as suggested. In the 2020 GBD study report, there is no combine prevalence and number of deaths for asthma and chronic obstructive pulmonary disease. As a result, we revised the text and provide the updated statistics from the 2020 report while maintaining the 2017 statistics also and both referenced. See lines 2-8 at page 3.

2. Page 5, study population: please briefly describe the sampling strategy used in SAGE.

Response: Thanks for the useful feedback. We revised the manuscript to reflect this. However, we effected this under data source and sampling because we believe is more appropriate under the data source compared to the study population. See line 14-20 at page 5.

3. Page 5, study population and outcome variable: since SAGE is a longitudinal study, it might be better to use data from both wave 1 and wave 2 to identify incident asthma cases. The current analsyes depending on the asthma question only from the wave 2 made this a cross-sectional study, which substantially limited the significance of this study.

Response: The focus of this paper is to quantify unobserved household-level residual variations in asthma episodes while simultaneously identifying critical risk factors associated with the disease. We agreed that using data from wave 1 and 2 might provide additional information BUT there was a challenge where over 50% of those who participated in wave 1 conducted in 2007-2008 dropped out of the study in wave 2 conducted in 2014-2015 and new samples were drawn to replace some of them. Also, the secondary data we used did not uniquely identify participants in wave 1 only, wave 2 only and those in both wave 1 and 2. This introduced some analytical challenges because in analysing both wave 1 and wave 2, the modelling become much complex because we need to take into account that majority of those in wave 1 did not participate in wave 2 and that new samples were introduced in wave 2. Thus, there is a mixture of repeated cross-sectional and longitudinal designs which must be considered when modelling based on wave 1 and 2 but this will require availability of further data (e.g. variables that uniquely identify participants in wave 1 only, wave 2 only and those in both wave 1 and 2) and also this kind of analysis will require much more efforts than that of the present study. We will continue to engage the owners of the data and if successful, we will implement a modelling strategy that will account for the mixture of repeated cross-sectional and longitudinal designs nature of the data in our future studies.

4. Page 5, explanatory variables: as this is an exploratory study, it is unclear why the authors only included these variables. Why neighborhood-level factors were not included? Many established risk factors mentioned in the background section were not included.

Response: We used secondary data in our analysis and except place of residence (urban/rural), no other neighbourhood/environmental covariates were available in the data. If the data were to contain geographical coordinates (latitudes/longitudes) of the respondents (this was not collected in the study), we could use that to extract neighbourhood/environmental/spatial covariates and include same in our model. Also, we explored all potential covariates in the available data through a combination of expert opinion, available literature, and statistical methodology for variable selection.

5. Page 7, statistical analyses: the authors only included variables with a p-value<0.2 from the univariable regression model in the multivariable regression model. This variable selection approach is problematic. More advanced approach such as the elastic net model or Lasso model with hyperparameters determined by cross-validations should be used to perform the variable selection. e.g., the glmmLasso package in R can be used to implement Lasso for gelearized linear mixed models.

Response: Thank you for this suggestion. First of all, we used expert opinion and available literature on deciding potential predictors of asthma episodes to arrive at all the variables presented in Table 1. After that, we applied the statistical methodology for variable selection using p<0.2 in the univariable (bivariate) analysis as a threshold to identify candidate set of variables that will enter the multivariable model which is a standard approach. We will consider the elastic net model or Lasso model suggestion in our future research.

6. Page 15: one major limitation is the cross-sectional design of this study: the current exposures to the risk factors may not be representative of the historical exposures before the onset of asthma. This needs to be discussed in the limitation section. Again, if asthma data is available from wave 1, I highly recommend the authors to use the data to identify incident asthma cases to avoid the cross-sectional design of the study.

Response: We already stated in the limitation that the nature of the data and the modelling approach could not allow for drawing effect of causation (see lines 19-20 at page 18), and we did not attempt to make any statement to suggest causation effect between the covariates and asthma episodes. We already provided response to the use of wave 1 and 2 in comment 3 which also addressed this.

Attachment

Submitted filename: Response_to_Reviewers_Editors_JA.docx

Decision Letter 1

Florian Fischer

19 Nov 2020

PONE-D-20-10825R1

Prevalence, socio-demographic and environmental determinants of asthma in 4621 Ghanaian adults: Evidence from Wave 2 of the World Health Organization’s Study on global AGEing and adult health.

PLOS ONE

Dear Dr. Aheto,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

PLease take into cnsideration thje point raised by Reviewer 2.

Please submit your revised manuscript by Jan 03 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Florian Fischer

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript has been improved and strengthened. I have rarely seen data on asthma in an African country and this work will add to that literature.

Reviewer #2: The authors did not adequately address my concerns, especially for the variable selection procedure. The response letter includes a statement that "we applied the statistical methodology for variable selection using p<0.2 in the univariable (bivariate) analysis as a threshold to identify candidate set of variables that will enter the multivariable model which is a standard approach", which is not true.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Dec 9;15(12):e0243642. doi: 10.1371/journal.pone.0243642.r004

Author response to Decision Letter 1


23 Nov 2020

Review Comments to the Author

Reviewer #1: The manuscript has been improved and strengthened. I have rarely seen data on asthma in an African country and this work will add to that literature.

Response: Thank you.

Reviewer #2: The authors did not adequately address my concerns, especially for the variable selection procedure. The response letter includes a statement that "we applied the statistical methodology for variable selection using p<0.2 in the univariable (bivariate) analysis as a threshold to identify candidate set of variables that will enter the multivariable model which is a standard approach", which is not true.

Response: Thank you for pointing this out. Our decision to use threshold of a p-value <0.2 is based on the discussion in the literature on traditional stopping rule and suggested optimal p-values. The literature on this topic provided a strong recommendation for using a p-value in the range of 0.15–0.20 (Hosmer & Lemeshow, 2013), although using a higher significance level has the disadvantages that some unimportant variables may be included in the model (Hosmer & Lemeshow, 2013). Typically, the stopping rule for the traditional choice for significance level is considered to be between 0.05 and 0.10 though it was also established that the optimum value of the significance level to decide which variable to include in the multiple regression model is suggested to be p<1 (Chowdhury & Turin, 2020; Harrell, 2001), which actually exceeds the traditional choices.

The above discussion in the literature is what informed our choice and that is what the authors meant by the statement "we applied the statistical methodology for variable selection using p<0.2 in the univariable (bivariate) analysis as a threshold to identify candidate set of variables that will enter the multivariable model which is a standard approach". Our choice of p-value<0.2 also lies between the maximum for the traditional rule and that of suggested p-value<1 which is an acceptable approach.

After extensive reading, we observed that there are other techniques such as Lasso, Elastic net, and Ridge regression approaches based on machine learning techniques which could provide optimal variable selection which we did not do in our current study. However, this machine learning approaches of variable selection requires extensive learning of the procedure and the software for implementation, and the authors will surely explore this in their future research work.

We revised the manuscript to highlight this under the limitations in lines 400-403 at page 18. Specifically, we inserted the statement “The use of p<0.2 as the stopping rule to identify candidate set of covariates in the bivariate model to be included in the multivariable model might not provide optimal variable selection for the covariates, although previous studies have provided a strong recommendation for using p-values in the range of 0.15-0.20 [58] as used in our study”.

References

Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression. New York: John Wiley & Sons, Incorporated, 2013.

Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health. 2020 Feb 16;8(1):e000262. doi: 10.1136/fmch-2019-000262. PMID: 32148735; PMCID: PMC7032893.

Harrell FE. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer, 2001.

Attachment

Submitted filename: Rebuttal_Letter_Reviewers_JA_AEY_23.11.2020.docx

Decision Letter 2

Florian Fischer

25 Nov 2020

Prevalence, socio-demographic and environmental determinants of asthma in 4621 Ghanaian adults: Evidence from Wave 2 of the World Health Organization’s Study on global AGEing and adult health.

PONE-D-20-10825R2

Dear Dr. Aheto,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Florian Fischer

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Florian Fischer

1 Dec 2020

PONE-D-20-10825R2

Prevalence, socio-demographic and environmental determinants of asthma in 4621 Ghanaian adults: Evidence from Wave 2 of the World Health Organization’s Study on global AGEing and adult health.

Dear Dr. Aheto:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Florian Fischer

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response_to_Reviewers_Editors_JA.docx

    Attachment

    Submitted filename: Rebuttal_Letter_Reviewers_JA_AEY_23.11.2020.docx

    Data Availability Statement

    Data is freely available upon making official request to WHO SAGE Team through the WHO website at http://www.who.int/healthinfo/sage/cohorts/en/. The data is provided to researchers freely but the WHO SAGE Team only releases the data to researchers upon request made directly to WHO, and individual researchers granted permission to use the data are not allowed to make the data (in any form) available to third parties. Any third party interested in the data must apply directly to the WHO SAGE Team.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES